Reports and Briefs on Neurology

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Report
Report

Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market

In-depth analysis of the epilepsy drug pipeline, including assessment of the clinical and commercial prospects of late-stage agents, unmet market needs, sales forecasts to 2019, and key opinion leader insight.

Published By Datamonitor
12 May 2010 $11400
Buy

Order this report by October 22nd 2010 and receive a 30% discount

To take advantage of this offer enter Promo Code TBI30 when prompted in the checkout

More information

Report
Report

Stakeholder Opinions: Traumatic Brain Injury - Hormonal therapy generates optimism

Analysis of traumatic brain injury epidemiology, unmet needs and pipeline treatments. Provides analysis of opportunities and threats facing developers of TBI treatments based on interviews with six key opinion leaders.

Published By Datamonitor
07 Apr 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential

Analysis of spinal cord injury epidemiology, unmet needs and pipeline treatments. Provides assessment of potential market value and analysis of opportunities and threats facing developers of SCI treatments based on interviews with key opinion leaders

Published By Datamonitor
05 Mar 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatness

This report assesses the current landscape of and future opportunities for therapeutic vaccines outside cancer, covering therapeutic vaccine approaches in cardiovascular and metabolic, CNS, autoimmune and infectious diseases.

Published By Datamonitor
17 Dec 2009 $3800
Buy
Report
Report

Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical development

Comprehensive analysis of the gene therapy clinical pipeline across all geographic and therapeutic markets, with key opinion leader insights. Identification of drivers and inhibitors to the commercial success of gene therapy.

Published By Datamonitor
10 Dec 2009 $3800
Buy
Report
Report

Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential

Analysis of the future potential of anticonvulsants market. Includes sales forecasts over 2009-2018 across the seven major markets (US, Japan, France, Germany, Italy, Spain, and the UK) of key marketed brands, generics, and pipeline agents.

Published By Datamonitor
08 Oct 2009 $15200
Buy

« | 1 | 2 | 3 | 4 | » »|

No help is available.